优信彩票

新聞中心

  培訓項目 更多+
  在線教育 更多+
微信圖片_20211214133409.jpg

掃描二維碼
關注微信平臺

qrcode_for_gh_8881cedb0364_430.jpg

掃描二維碼
關注微信平臺

18210832384
  新聞動態 您的位置:主頁 > 新聞中心 > 新聞動態

專題報告>行業資訊與研究


發布時間:2017-04-06 19:22:31      來源:      瀏覽次數:4890次

        Overview of the Selection and Design on Guangji Pharmacy Output Chinese Herbal Varieties  


一、    緣起 

ORIGIN 

        湖北廣濟藥業股份有限公司(簡稱”廣濟藥業”)是中國第一批高科技上市制藥企業之一,也是國際上生產核黃素(維生素B2)的知名企業,具有很強的經濟實力和品牌效應。 

        Hubei Guangji Pharmaceutical Corp. PLC. (abbr.—Guangji Pharmacy), with her strong capital power and brand force, is one of the earliest high-tech public pharmaceutical enterprises and an internationally well-known lactoflavin manufacturer. 

        該公司為擴展業務范圍和企業規模,決定將制藥業務從西藥(化學藥)延伸到中藥(天然藥物)領域,并為此購并了湖北回春藥業集團公司(中藥生產企業)。 

       In order to expand her business scope and size, Guangji Pharmacy decided to extend the pharmaceutical business from western medicine (chemical medicine) to Chinese herbal medicine (natural medicine), and therefore incorporated Hubei Huichun Pharmacy Group Co. (a Chinese herbal medicine manufacturer). 

        作為一家具有長遠戰略眼光,而且實力雄厚的公眾公司,廣濟藥業沒有把其新開展的中藥業務局限在中國國內市場,而是進一步瞄準了國際市場,特別是增長迅速的北美市場。 

        As a powerful public company with a long-term strategical insight, Guangji Pharmacy does not confine her traditional Chinese medicine (TCM) business within the domestic market but aim at the international market, specially the increasingly developing north American market. 


        為此,廣濟藥業于2000年初委托以作FDA通關聞名的美國伊利諾伊斯州神州上藥國際集團有限公司(Orienature’s Care Group International Inc)將回春藥業公司中成藥品種以及委托中國中醫科學院醫藥保健品研制中心設計的中藥產品,共65個品種,作進入美國市場的FDA通關工作(包括審核或修改質量標準、設計英文標簽、向FDA申報進口和上市銷售許可)。 

 For this purpose, Orienature’s Care Group International Inc., a well known company for its service on clearance with US Customs and FDA, is entrusted by Guangji Pharmacy for the clearance of her 65 output products combining Huichun Pharmacy Co.’s Chinese patent medicines and herbal products designed by the R&D Center of the China Academy of Traditional Chinese Medicine (CATCM). The services involve examining or revising the quality standards, designing English labels and declaring the import and market admission to FDA. 

        并委托美國加州中國醫藥發展公司作這些產品在北美的銷售總代理。中國醫藥發展有限公司是中國中醫研究院國際醫藥公司于1995年在美國加州發起設立的中藥專營公司,主營從中國大陸向北美引進新型中藥產品,該公司對美國中醫藥行業狀況十分熟悉,并有較高的行業知名度。 

Besides, California China Medicine Development Corp. is the general agent for Guangji output herbal products in the U.S.. A professional Chinese herbal medicines management company launched by the China Academy of TCM International Medicine Corp. in California in 1995, California China Medicine Development Corp., familiar with the Chinese herbal medicine industry of the U.S. and enjoying a high reputation, primarily runs new fashion Chinese herbal medicines introduced from the mainland of China.  

        基于上述關系,并為協作完成廣濟藥業出口中成藥的遴選、設計、出口通關的總體目標,中國醫藥發展有限公司、神州上藥國際集團有限公司、中國中醫研究院醫藥保健品研制中心聯合成立“廣濟藥業出口中藥品種遴選設計工作課題組”(以下簡稱“本課題組”)。課題組由中醫藥臨床、中藥工程技術、中醫藥文獻、醫藥市場調研、英語、涉外專門法律等方面的專業人員及輔助人員組成,全面執行廣濟藥業的這一委托項目。 

        Basing on the above relations, the three parties—China Medicine Development Corp., Orienature’s Care Group International Inc and the R & D Center of CATAM, for the overall aim of the selection, design and clearance with FDA and Customs on Guangji’s output Chinese herbal varieties, jointly established “Guangji output Chinese herbal varieties selection and design workgroup”. This group is composed of professionals on clinical traditional Chinese medicine (TCM), Chinese materia medica engineering technique, TCM literature, medicine market research, English language, and specialized foreign laws and other supporting staff, carrying on this project all around. 

二、          產品遴選與設計原則 

PRINCIPLES ON SELECTION AND DESIGN  

        中醫藥學有兩千多年歷史,千百年來積累下來的中醫藥典籍汗牛充棟,流傳下來的中藥方劑(固定處方)多達數十萬首。目前全國各藥廠生產的中成藥產品、各醫院內部中藥制劑以及保健品廠生產的中藥型保健品有上萬種之多。如何在浩如煙海的中藥方劑和成千上萬的中藥成品中找到理想的品種作為廣濟藥業的出口中藥產品,這是課題組面臨的首要問題。為此,本課題組確定了廣濟藥業出口中藥品種的遴選方針。 

 Two thousand years’ history of TCM has left us a great number of classics and several hundred thousand of formulae. Now in China there are thousands of Chinese patent medicines manufactured by pharmaceutical plants, hospital internal Chinese herbal preparations, and herbal health care products made by health care manufacturers. How to find ideal varieties as Guangji’s output Chinese herbal medicines from numerous Chinese herbal formulae and patent medicines is essential for the workgroup. The workgroup therefore, formulated principles for the selection of Guangji Pharmacy herbal medicines. 


    1.     市場定位 

        根據“以市場為導向”的原則,我們首先要確定廣濟藥業出口中藥品種的市場定位,即這些產品將由誰來購買與使用。鑒于廣濟藥業的企業性質、對美市場專項投資規模、美國草藥產品市場的特點,以及中國醫藥發展公司(以下簡稱SD公司)在北美的工作基礎和客戶資源,我們把廣濟藥業出口美國中藥產品定位于:以專業市場(替代醫學的醫療市場)為主,專門市場(保健食品市場)為輔,即主要針對中醫針灸以及正脊、自然療法等替代醫療機構提供中藥有療效優勢的治療性或輔助治療性中成藥品種,并為保健食品市場(保健食品專營店與連鎖店)提供幾個有較好市場基礎的中藥保健產品。終端消費(使用)人群為:華裔和日裔、韓裔等相信中醫藥的亞裔人群,以及相信中醫藥或愿意嘗試中醫藥的其它族裔(如白人、墨西哥人、黑人)人群。 

    1.        Market Orientation 

According to the principle of “orienting with the market”, firstly we defined the market orientation for the output herbal varieties, i.e., who will purchase and use the products. In regard to Guangji Pharmacy’s enterprise property, investment scope special to the U.S. market, and characteristics of the U.S.’s herbal product market, we orient Guangji output herbal medicines as followed: professional market (medical treatment market of alternative medicines) the first, specialized market (health care food market) the second, i.e., primarily providing herbal medicines with advantages of treatment or subsidiary treatment for alternative medical institutions concerning acupuncture, chiropractic, and natural remedies, etc., and providing the health care food market with several herbal health care products which have had a sound market base. Terminal consumers (users) involve American Asians who trust TCM such as American Chinese, Japanese and Korean, and other Americans of different origins who believe TCM (such as the white, Mexican and black). 


    2.     功用主治定位 

        藥品是由有疾病的人—患者使用的一類特殊產品。藥品的市場取決于它的適應癥—主治病癥的發生率,它對該病的療效及其替代性產品的數量與療效。基于前文所述市場定位,我們進一步把廣濟藥業出口中藥產品的功效主治定位為針對北美地區西藥療效不理想或毒副作用太大而中藥確有療效優勢的常見病、多發病、疑難病,如抑郁癥、流感、花粉過敏癥、前列腺肥大、老年性癡呆、慢性結腸炎、慢性乙型肝炎、丙型肝炎、慢性腎炎、更年期綜合癥、子宮肌瘤、痛癥、中風后遺癥、冠心病、高脂血癥、糖尿病、惡性腫瘤或其放化療的恢復期等等。廣濟藥業出口中藥的目標病癥見附表三《廣濟藥業出口中藥適應癥——西醫》。 


     2.        Orientation on Functions and Principal Indications 

Medicine is a kind of special product used by patients. The market of a certain medicine is subjected to the happening rate of the principle indications and efficacy of the medicine, and the number and potency of alternative products. Basing on the market orientation stated above, we oriented the functions and indications of Guangji output herbal products to common diseases, frequently happened diseases and difficult diseases, such as depression, flu, pollen sensitivity, prostatic hyperplasia, senile dementia, chronic colonitis, chronic hepatitis B, hepatitis C, chronic nephritis, climacteric syndrome, hysteromyoma, pains, sequela of apoplexy, coronary heart disease, high blood fat, diabetes, malignancy, etc., on which Chinese herbal medicines have an obvious potency advantage against that of western medicines which have poor efficacy or side effects. See Table 3 for the target diseases of Guangji products. 


     3.         處方與藥味的選擇 

        處方及其組成成份(藥味)是決定中藥產品療效的首要因素。在確定了產品的功用主治定位以后,選擇最恰當的處方就成為工作的必須,從某種意義上說,品種的篩選即是處方的篩選。我們在篩選廣濟藥業出口中藥的處方時,依次遵循以下七條原則:其一,該處方經臨床和實驗研究證明對目標疾病具有顯著的治療效果—療效確切,與西藥同比具有優勢;其二,無毒副作用或毒副作用很小—使用安全;其三,處方選擇以辨病施治為主,辨證使用為輔,以方便在北美地區的推廣應用;其四,無美國FDA及瀕危野生動植物保護委員會禁用的成份—合乎法律;其五,藥味組成相對簡單,藥材資源豐富,避免使用特別冷僻和昂貴的成份;其六,受公認程度較高,有正式質量標準;其七,被選中的處方之間重復性小。上述原則的目標是要從古今中醫成方成藥中篩選出“高效、安全、新型、實用”的品種。 高效---對目標疾病有療效;安全----使用安全;新型----劑型現代化,使用攜帶方便;實用---有廣闊的市場需要,適用面廣。 

         按照上述原則遴選的中藥成方成藥直接納入到廣濟藥業出口中藥品種系列中。我們力求從已在中醫藥界流通的成方成藥中篩選出我們所要找到的處方。但是對于有些目標疾病并找不到,或目前尚未找到理想的現有成方成藥,為此,本課題組根據中西醫藥理論以及當代臨床與實驗研究成果,精心擬定處方,研制出新產品。部分新品種是我們自己多年來的臨床與實驗研究成就,在國內外具有領先性。對于有些成方,我們根據自己的研究作了修改,其效果優于原方。我們所研制的新產品或改進的產品,也圍繞著“高效、安全、新型、實用”的目標進行。 

    3.        Selection on Formulae and Herbs 

Formulae and components (herbs) are the essential factors for the efficacy of Chinese herbal products. After the orientation on functions and principal indications, it came to a must to select the most suitable formulae. To select varieties, to some degree, is to select formulae. In  the process we followed seven principles listed below. 

  1)       Through clinical and laboratory research, the selected formula is demonstrated to have an obvious efficacy on a target disease—definite efficacy, superior to western medicines. 

2)       Have no or little side effect—safely use. 

3)       On selecting formulae, place priority to treatment basing on an overall analysis of the illness, and then to discriminatingly use of medicines for the convenience of promoting products in the north America. 

4)       Contain no components prohibited by FDA or       —accord with laws. 

5)       Composition of herbs is relatively simple; selected herbs have abundant herbal resources; avoid using rare and costly components. 

6)       Broadly recognized, have formal quality standards. 

7)       Little repeat among selected formulae. 

Above principles aim at selecting high-effect, safe, new-pattern and practical formulae from ancient and current Chinese patent medicines. High-effect means having potency on target diseases; safe means safely use; new-pattern means modern dosage forms convenient for use and carriage; practical means having broad market needs and application scope.  

Chinese patent medicines and formulae selected on above principles are directly incorporated into the Guangji output Chinese herbal product series. We try to select formulae from the patent medicines and formulae that have circulated in market. For those target diseases on which we have not had or found ideal patent formulae or medicines, our work group aboratively designed formulae and developed new products, combining both Chinese and western medicine theories and contemporary clinical and laboratory research achievements. Some of the new varieties were developed through our several-year clinical and laboratory research and are now leading in China. Regarding some of the patent formulae, we revised their formulation so as to enable them to have better effects than that of the original. The revised and new products we developed also followed the principles of “high-effect, safe, new-pattern and practical”. 


     4.  劑型選擇 

        中藥的劑型既影響到它作為商品的流通及其為消費者所使用的方式,也影響它作為藥品在患者體內的吸收及其效用的發揮。廣濟藥業出口中藥的目標市場是海外,首先是北美,因而在其劑型的選擇上要符合北美消費者的使用習慣與偏好,適宜于長途運輸和較長期的保存,同時兼顧中藥劑型的特點以及中藥劑型與效用的關系。為此,我們在劑型的選擇上以用量小、攜帶和使用方便、易于運輸與保質期長為原則。內服劑型選擇的優先次序為:膠囊、沖劑(顆粒)、片劑。次用量控5粒(片)、2袋以內,日用次數控制在3次以內。內服制劑是廣濟藥業出口中藥的主體,這批產品的外用制劑共只有4個,分別為油劑、洗劑和軟膏劑。(見附表一) 

    4.        Selection on Dosage Forms 

The dosage forms of Chinese herbal medicines may influence not only their circulation as products (commodities) and the way that consumers use them, but the absorption in a human body and the exertion of their potency. The target market of Guangji output herbal medicines is overseas market, primarily the north America, and therefore the selection on dosage forms should meet the habits and preference of consumers in north America, suit for long-distance transport and long-term storage. The dosage forms for internal medicines rank as followed: capsule, granule and tablet. Daily value is within five capsules, two bags, three times daily. Internal preparations take the principal part in Guangji output herbal products. There are only four external products with dosage forms of oil,  liquid and ointment.  


三、          工作方法和工作結果 

    1.     工作階段與方法 

        本課題組自2000年3月份全面開展本項目的工作,歷經近12個月的時間完成廣濟藥業出口中藥的遴選與設計。工作分為三個階段。第一階段:2000年3-8月份,目標疾病和目標方藥的國內遴選。在這一階段我們通過查閱大量的中醫藥(含中西醫結合)專業文獻,并走訪了近百名資深中醫和中西醫結合臨床專家,初步確定廣濟藥業出口中藥品種的目標病癥和目標方藥。第二階段:2000年9-11月份,目標疾病和目標方藥的北美確認。在這一階段,我們走訪了美國洛杉磯、芝加哥、紐約、加拿大多倫多、溫哥華等地區的三十多家診所,五十多家藥店,參加拉斯維加斯的大型草藥博覽會和加州中醫師公會學術研討會,并查閱北美中醫藥、天然醫藥文獻,對前一階段所遴選的目標疾病和目標方藥進行評議、咨詢和修改,使得目標疾病和目標方藥更加明確。穿插在以上兩個階段的工作之中,我們還進行了自主研制品種的實驗研究和臨床觀察工作。第三階段:2000年12月-2001年2月份,資料整理與標準制訂。在這一階段,我們就所確定的目標方藥--廣濟藥業出口中藥品種進行系統的資料整理,以最終確定每一個品種的處方、生產工藝、臨床與實驗研究綜述,使用說明書等,并進而制訂或確定每一個品種的技術標準。至此,廣濟藥業出口中藥品種的遴選與設計工作結束。 

Ⅲ. Working Method and Result 

    1.        Working stage and method 

We started the project from March 2000, and spent about 12 months on selection and design. The work spans three stages.  

First: March~ August 2000, selected target diseases and formulae in China. In this stage we primarily fixed target diseases and formulae through reviewing a great number of professional TCM (including combination of Chinese medicine and western medicine) literatures, and visiting about a hundred senior traditional Chinese physicians and clinical experts. 

Second: September~ November 2000, fixed target diseases and formulae in the north America. We visited over thirty clinics and fifty pharmacies in Los Angeles, Chicago, New York, Toronto and Vancouver, etc., and took part in the large-scale Natural Product Expo in Las Vegas, and California Traditional Chinese Physician Guild Proseminar, and referred to many north American TCM and natural medicine literatures, and evaluated, discussed, consulted and revised on the selected target diseases and formulae in the previous stage. During the two stages of work we also conducted laboratory research and clinical observation upon our independent R&D varieties. 

Third: December 2000~February 2001, arranged materials and formulated standards. We systematically arranged materials of fixed objective formulae—Guangji output herbal varieties and settled each variety’s formula, manufacturing technique, overview of the clinical and laboratory research, and direction for use, and thereof formulated and settled each variety’s technique standard. Up to then, the selection and design on Guangji output Chinese herbal varieties finished. 


    2、工作結果 

        對于本項目的工作結果(產品遴選與設計),可以從以下三個技術層面加以概括。 

1處方來源:65個品種的處方來源由三個部分組成:歷史經典方(含經方化裁)20首,當代經驗方34首,自主研發方11首。歷史經典方為清代以前形成的,現代還在使用而且臨床療效確切的著名方劑;當代經驗方為20世紀以來中醫藥臨床經驗方(含成藥處方),療效確切,而且切合北美市場需要;自主研發方為直接根據北美市場需要而新組的方劑。處方組成成份(藥味)需符合美國FDA及農業部有關規定,需要替換的,在保證療效的前提下予以替換。 

    2.        Working result 

As for the result of the project, we may summarize from the following three technical aspects. 

1)       Formulae sources 

Formulae of the 65 varieties are composed of  three parts: 20 historical classical formulae (including      ), 34 contemporary classical and proved formulae, 11 independent R&D formulae. The historical classical formulae we selected are those formed before Qing Dynasty and still used with definite clinical efficacy now. The contemporary classical and proved formulae are those formed in 20th century, having definite efficacy, and suitable for the north American market. The independent R&D formulae are new and for the very needs of north American market. Components (herbs) of formulae should accord with regulations of FDA and Agriculture Ministry, and certain components, on the basis of ensuring the efficacy,  could be replaced when necessary. 


    2生產工藝:生產工藝是決定劑型的關鍵因素。


        為了保證所選用的品種既劑量小,使用方便,便于運輸、攜帶和貯存,又要有足夠的效能(藥力),廣濟藥業出口中藥品種均采用現代工藝生產,應用現代萃取工程技術提取有效成份,應用現代干燥技術進行干燥處理,應用現代制劑工藝造出劑型。設計工藝是一項技術性很強的工作,也是中藥產品研制的關鍵性技術環節之一。我們在設計廣濟藥業出口中藥的生產工藝時,采用了下列三種方式:原方原工藝原劑型、原方新工藝新劑型、新方新工藝新產品。 

        原方原工藝原劑型:我們在確定廣濟藥業出口中藥品時,在現有成方制劑中如果發現有在功效、主治病癥、處方、劑型及生產工藝方面都符合前述要求的產品,則直接采用,并依據原工藝進行生產(屬仿制產品),如銀翹解毒顆粒。部分品種基本依據原工藝,但在某些環節上有必要的改進,如元胡止痛膠囊中的白芷提取方式有所改進。 

        原方新工藝新劑型:如果現有成方制劑在功效、主治病癥、處方方面較理想,但劑型及生產工藝不合要求的品種,我們則采用原處方重新設計新生產工藝。湯劑、傳統的丸劑(指直接用藥材原粉制成的丸劑)、散劑(指直接將藥材粉碎所得粉末劑)和直接以藥材原粉壓成的片劑,采用現代萃取工藝、干燥技術和制劑工藝制成膠囊劑或沖劑。如大黃  蟲丸更新為膠囊(金匱化瘀膠囊),排石湯改為錢草尿石顆粒,升血湯更新為參芪生血膠囊。 

        新方新工藝新產品:部分現有成方成藥,我們已知其劑型、處方、功效主治,但無法知道其生產工藝,此次我們為其重新設計工藝。至于由本課題組自行擬定的新處方(包括在經方基礎上加減化裁而形成的新處方),其生產工藝自然為全新設計,如龍虎愈肝康膠囊、芪葛聰明膠囊。 

在這批廣濟藥業出口中藥品種中,屬第一種情況者20種,占30.8 %,;屬第二種情況者,32種,占49.2 %;屬第三種情況者13種,占20 %。 

    2)       Manufacturing Technique 

Manufacturing technique is the crucial factor for the dosage forms of herbal medicines. In order to ensure that the selected varieties are not only in small dosage, convenient for use, transportation, carriage and storage but have enough potency, all the Guangji output herbal varieties are manufactured with modern technique, e.g., extracting active components with modern extract technique, seasoning with modern drying technique, using modern preparation technique for dosage forms. Designing techniques is a high technical work, and one of the crucial technical aspects of the R&D of Chinese herbal products. We followed three ways when designing the manufacturing techniques: 

l          Original formula, original technique, original dosage form 

l          Original formula, new technique, new dosage form 

l          New formula, new technique, new dosage form 

l          Original formula, original technique, original dosage form—in the selection process, if the efficacy, diseases, formulae and dosage forms of the existing patent remedies met the demands of the above mentioned products, we would adopt them directly, and manufactured according to the original techniques (belong to copied products), e.g., Yinqiao Jiedu granule. For some varieties we primarily use their original techniques, but made some necessary changes, e.g., the extract method on dahurian angelica root in Yuanhu Zhitong has been improved. 

l          Original formula, new technique, new dosage form—if the efficacy, diseases and formulae are suitable, but dosage forms or manufacturing techniques do not meet the needs of the varieties, we would adopt original formulae but design new manufacturing techniques. We transferred soup, traditional pill (made of initial powder of herbs directly), powder (directly made of powder of herbs) and tablet directly made of herbal initial powder into capsules and granules with modern extract technique, drying technique and formulation technique. For instance, we renewed Dahuangchong pill into capsule (Jingui Huayu capsule), Paishi Soup into Qiancao Niaoshi granule, and Shengxue Soup into Shenqi Shengxue capsules.  

l          New formula, new technique, new dosage form—for some existing formulae and medicines, we knew their dosage forms, formulae and efficacy, but do not know their manufacturing techniques. We redesigned techniques for them. Concerning the new formulae we designed independently (including the new formulae plus or minus based on classical formulae), we made wholly new manufacturing techniques, e.g., Longhu Yugan capsule, Qige Congming capsule. 

In this series of Guangji output herbal products, 20 varieties belong to the first category, taking 32.8% of the total; the second category includes 32 varieties, taking 49.2%; the third 13, taking 20%. 


    3質量標準:質量標準是產品的最終技術文件,它包括產品的名稱、處方、制法、性狀、鑒別、檢查、功能與主治、用法與用量、貯藏等項目。我們對所遴選的65個廣濟藥業出口中藥品種均確定了質量標準,其中20個原方原劑型原工藝的產品依據該產品的原質量標準,32個原方新劑型新工藝的產品重新設定了質量標準,而13個新方新工藝新產品也新設定了質量標準。此外,作為生產過程的質量控制環節,我們按照美國FDA的法規要求規定相關環節上的質量控制指標,如重金屬含量(可能因藥材的產地不同而致重金屬含量超標)、微生物(可能因生產場所衛生條件問題及包裝品質量導致超標),以確保廣濟藥業出口中藥產品不僅在理論上或資料上質量合格,而且在實際產品上也質量合格。 

    3)       Quality Standard 

Quality standard is the ultimate technical document, including a product’s name, formula, manufacturing method, property, differentiate, examination, function and principle indications, usage, dosage and storage, etc.. We have set the quality standards for all the 65 Guangji output herbal varieties, within which 20 varieties with original formulae, dosage forms and techniques keep their original standards, 32 varieties with original formulae, new techniques, new dosage forms use the redesigned standards, and the rest 13 varieties with new formulae, techniques and dosage forms also have newly designed standards. Besides, for the quality control procedures of the manufacturing process, we regulated the quality control criteria according to FDA regulations, e.g., content of heavy metal (differences in the producing areas for herbal raw materials may cause the exceeding of the content of heavy metal), microorganism (the sanitary condition of manufacturing place and quality of packing materials may cause exceeding), so as to guarantee not only the theoretical and material qualification of Guangji Chinese herbal output products but the quality of manufactured products.


        后記:廣濟藥業出口中藥的第一批產品39種于2001年9月份出廠,10月份辦理出口美國手續,11月初全部一次性通過FDA清關而獲準進入美國市場。該產品一進入美國便受到市場的歡迎,第一批產品立即全部現款售出。在目前我國中藥出口多年徘徊不前及美國天然醫藥產品市場低迷的情況下,這一佳績是非常難得,非常令人振奮的,這也襯托出廣濟藥業出口中藥的前期準備工作是成功的。 

Postscript 

The first 39 varieties of Guangji output product seires left plant in September 2001. In October we conducted the procedures to output to the U.S. In early November all the products passed the clearance with FDA and customs and were admitted the U.S. market. As soon as they came into the U.S., these products were warmly welcomed and  sold off. In the current situation when the output of Chinese medicines have fluctuated for many years and the U.S. natural health care product market is at a low ebb, this achievement is valuable and exciting, and reflects that the previous preparation for Guangji output herbal medicines is successful. 



                    廣濟藥業出口中藥品種遴選設計課題組 

Guangji Pharmacy output Chinese herbal varieties selection and design workgroup 

            Sinomedecal Development, Inc 

Orienature’s Care Group International,Inc 

                   中國中醫研究院醫藥保健品研制中心



上一篇:《1994年飲食補充劑健康與教育法》

下一篇:中藥在美國遭封殺,中國企業該作些什么?

關于我們誠聘英才|聯系我們

電話:(+86)18210832384 ;地址:中國北京市東城區東直門內南小街16號 郵編:100700

Copyrights  2008-2017 中國中醫科學院中醫藥科技合作中心 All Rights Reserved &nbsp